1 mrc perspectives on the changing uk research agenda 14 march 2007 university of birmingham mike...
TRANSCRIPT
1
MRC perspectives on the changing UK research agenda
14 March 2007
University of Birmingham
Mike Davies, MRC
2
MRC Mission
• To encourage and support high quality research with the aim of maintaining and improving human health;
• To produce skilled researchers, and to advance and disseminate knowledge and technology to improve the quality of life and economic competitiveness in the UK;
• To promote dialogue with the public about medical research.
3
• Now…
MRC spends about £530 million of public money per annum:
• providing funding for research programmes and infrastructure, and by investing in training and employment both in universities and in MRC's own research centres
• from basic discoveries right through to developing treatments,
• to achieve health benefits as quickly as possible
• with an increasing emphasis on prevention
Medical Research Council
4
MRC Background - Facts & FiguresFunds spent in 2005/06
• over £50m on training researchers in universities and hospitals
Support over 3,500 people in UK & overseas• 3 research institutes• 29 research units
> 3,000 researchers supported by MRC-funded programmes in universities & hospitals (including 15 MRC Centres)• 350 Research Fellowships• 85 Career Establishment Grants/New Investigator Research
Grant holders• 726 Post-doctoral researchers on MRC grants
5
MRC Strategy
6
Council and the Boards
NEW STRATEGY BOARD
RESEARCH BOARDS
HSPHRB, IIB, MCMB, NMHB, PSCSB
CO
LLEG
ES
O
F E
XP
ER
TS
STRATEGY & PORTFOLIO OVERVIEW GROUPS (SPOGS)
COUNCIL
OTHER AWARDS PANELS
(Competitions)
TRAINING AND CAREER DEVELOPMENT BOARD
RESEARCH CAREER AWARDS PANELS
7
Translational Research
8
Delivering Medical Research
Basic Research
Clinical Research
ExperimentalMedicine
PopulationSciences
Implementation & Delivery
Tran
slation
al research
9
Clinical Candidate Development Commercialization
Cumulative
Investment
£600 M
£270-320 M
£110-160 M
£10-30 MRisk
Target
Identification
and
Validation
Assay
Development
Lead
Generation
Lead
Optimization
Pre-Clinical
Development
Phase
1
Phase
11
Phase
111
Registration Global
Launch
Global
Optimization
The Risk/Cost/Time Development Paradigm
Time8 – 12 Years
Hypothesis
Generation1. Drug Discovery and Biomarkers
2. Experimental Medicine
3. Methodological Research
10
Spectrum– recent targeted initiatives
Basic Research
Clinical Research
ExperimentalMedicine
PopulationSciences
Implementation & Delivery
Tra
ns
latio
na
l res
ea
rch
MRCT Drug Discovery Biobank launched
Exp Med initiative
Clinical Research Facilities
•Population Health Network•Biostatistics – capacity build
•Translator awards•Translational Centres•Biomarkers initiative•University partnerships•NPRI
Methodological/Implementation
11
Comprehensive Spending Review
2007
12
CSR 2007 Priorities
Basic Research
Clinical Research
ExperimentalMedicine
PopulationSciences
Implementation & Delivery
Tra
ns
latio
na
l res
ea
rch
•Lifelong Health•Fundamental insights•Energising clinical research •Health of Disciplines•Translation – push & pull
13
Lifelong Health
Basic Research
Clinical Research
ExperimentalMedicine
PopulationSciences
Implementation & Delivery
Tra
ns
latio
na
l res
ea
rch
Early origins of health and disease
Healthy children
Elderly
14
Fundamental insights into better health
Basic Research
Clinical Research
ExperimentalMedicine
PopulationSciences
Implementation & Delivery
Tra
ns
latio
na
l res
ea
rch
Gene regulation
Translating genomic knowledge into improved health
Integrative/systems biology
Regenerative medicine/stem cells
15
Energising Clinical Research - Targeting opportunities and needs
Basic Research
Clinical Research
ExperimentalMedicine
PopulationSciences
Implementation & Delivery
Tra
ns
latio
na
l res
ea
rch
Diseases of modern life
Innovation in healthcare technologies
New approaches to prevention and public
health
Neglected populations
Orphan Areas – unmet clinical needs
Linking cohorts and using the data goldmine
16
Health of Disciplines
Basic Research
Clinical Research
ExperimentalMedicine
PopulationSciences
Implementation & Delivery
Tra
ns
latio
na
l res
ea
rch
New generation of Clinical scientists
Partnerships: chemical biology, predictive toxicology, clinical pharmacology, pathology
Clinical and public health methodological research
Targeted initiatives with Devolved Administrations
17
Translation – push and pull
Basic Research
Clinical Research
ExperimentalMedicine
PopulationSciences
Implementation & Delivery
Tra
ns
latio
na
l res
ea
rch
Applied Research + Co-operation Fund
Applied R&D close to implementation or commercialisation
Partnerships with industry - NICE
Targeted initiatives – Research Impact Monitoring Programme and translators
18
Single Health Research Fund
19
Single Health Research Fund
Opportunity to improve translational research in UKthrough the Single Health Research Fund
• Announcement by the Chancellor in March 2006 budget of a single ring-fenced budget to support health research funded by MRC and the NHS R&D programme
• Sir David Cooksey led the review into publicly funded health research in the UK
• The Chancellor announced the outcome of the review in his pre-budget speech on 6 December
20
Ideas on the health research base
• Problems in translation lie in gaps between:• Clinical / basic science and new intervention• Getting evidence-based intervention into practice
• DH should provide a stronger “user” voice in medical research priority setting.
• Relative payback from basic & applied medical research unknown. We need evidence.
• Peer review, career paths, and NHS environment discourage applied health research.
21
Ideas for innovation and industry
• A clearer health research strategy will help engagement and industry investment
• A new, more strategic, approach to adoption of new ideas / technologies in NHS
• Shorter drug development process• Better experimental medicine / markers / models• Streamline clinical trials • Fast-track products for priority areas (UK Priority Health Research
Projects)• Earlier NICE / HTA involvement• More conditional licensing of new products
• Remove barriers to collaboration (e.g. VAT) and gaps in translation
• Sustain and build on excellent research base – basic and clinical
22
MRCNIHR
Treasury
SoS Health SoS DTI
DG OSIDG R&D OSCHR
TMFB
23
OSCHR
• Chaired by John Bell
• CEOs of MRC and NIHR• Directors General of OSI and DH R&D (England)• Three others
• Sets overall health research strategy
• Approves bids to CSR, allocates funds between MRC and NIHR
• Promotes joint working
• Annual report to Parliament, monitors delivery
• Oversees Translational Medicine Funding Board
24
MRC Portfolio of Vision Research (1)
• MRC spends ~£2.5m pa on research relevant to vision
• Current support covers whole spectrum from basic underpinning to surgical treatments
• Support includes research grants, new investigator awards and personal fellowships
• Also consider proposals trials and epidemiological studies
a
25
MRC Portfolio of Vision Research (2)
Examples of research supported
• Molecular genetics of human retinal degeneration (MRC HGU); genetic susceptibility to AMD (Cambridge)
• Plasticity in the visual cortex in amblyopia (Cardiff)
• Visual Developmental disorders
• Improving surgical techniques for wet AMD (Moorfields/UCL)
• Stem cell research: 4 awards made under call including development of retinal stem cell therapies (Institute of Ophthalmology)